All In Biotech

Drug Trial Radar · NCT00680953

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis

A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)

Last checked: Nov 20, 2026Latest source record: Mar 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,262

Actual

Start

May 2008

Primary completion

Jun 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
May 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)

Conditions

  • Osteoporosis

Interventions

  • DenosumabDrug

    Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

  • PlaceboDrug

    Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

  • Alendronate sodium hydrateDrug

    Oral tablet once a week for 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to PlaceboTime frame: Baseline to 24 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Fukuoka, Japan

  • Site not named

    Osaka, Japan

  • Site not named

    Sapporo, Japan

  • Site not named

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.